“ABT-263 is unlikely to be approved for the clinical treatment of solid tumors due to both on-target (thrombocytopenia) and off-target (neutropenia) toxicities”
Orthotopic auxiliary partial liver xenotransplantation induces thrombocytopenia in rhesus monkeys following liver xenotransplantation (every recipient developed severe thrombocytopenia).
“Strikingly, every recipient developed severe thrombocytopenia, graft thrombosis, and thrombotic microangiopathy, which ultimately culminated in graft dysfunction.”
Animalsfollowing liver xenotransplantation6-, 8-, and 10-gene-edited porcine donors
Nicotinamide decreases thrombocytopenia in an ITP murine model.
“Supplementation with NAD+ precursor nicotinamide (NAM), but not nicotinamide mononucleotide (NMN), increased Treg frequency and ameliorated thrombocytopenia in an ITP murine model”
“galacto-conjugation reduces Navitoclax-induced platelet apoptosis in human and murine blood samples treated ex vivo, and thrombocytopenia at therapeutically effective concentrations in murine lung cancer models.”
Animalscompared with navitoclax; at therapeutically effective concentrations; murine lung cancer modelsgalacto-conjugated prodrug
Thrombocytopenia is linked with lower overall survival in humans (standard reference limits) (HR 1.58, 95% CI 1.32-1.89).
“thrombocytopenia (HR, 1.58; 95% CI, 1.32-1.89), and, especially the concomitant presence of anemia and thrombocytopenia (HR, 4.75; 95% CI, 2.98-7.55) were associated with inferior overall survival.”
Thrombocytopenia is associated with death from liver disease in humans (UK individuals with isolated thrombocytopenia).
“The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”
HumansUK individuals with isolated thrombocytopenia
Thrombocytopenia is associated with liver cancer in humans (UK individuals with isolated thrombocytopenia).
“The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”
HumansUK individuals with isolated thrombocytopenia
Thrombocytopenia is associated with nonmalignant liver disease in humans (UK individuals with isolated thrombocytopenia) (Absolute risks <1–2% with normal platelet count, 2–4% with isolated mild thrombocytopenia, and 3–7% with isolated moderate-severe thrombocytopenia).
“The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”
HumansUK individuals with isolated thrombocytopenia10 years
Thrombocytopenia is associated with death from hematological disease in humans (Isolated mild thrombocytopenia) (Absolute risk <1% across all age and sex categories with isolated mild thrombocytopenia).
“the relative risk of haematological disease and death from haematological disease was increased in isolated mild or moderate-severe thrombocytopenia”
Thrombocytopenia is associated with hematologic disease in humans (Isolated mild thrombocytopenia) (Absolute diagnosis risk ≤4% in UK individuals and ≤7% in Danish individuals versus ≤2% with normal platelet count and hemoglobin).
“the relative risk of haematological disease and death from haematological disease was increased in isolated mild or moderate-severe thrombocytopenia”
Multidisciplinary mhealth rehabilitation lowers the risk of thrombocytopenia in humans (grade 1 or higher; abdominal cancer patients undergoing CCRT; compared with standard care) (16.1% vs. 34.6%).
“lower incidences of ≥G3 leukopenia (5.4% vs. 19.2%, p=0.037) and ≥G1 thrombocytopenia (16.1% vs. 34.6%, p=0.026).”
Human trialgrade 1 or higher; abdominal cancer patients undergoing CCRT; compared with standard caren = 111
Frailty is linked with a higher risk of thrombocytopenia in humans (geriatric cancer patients receiving chemotherapy) (OR = 11.13, p = 0.021).
“Frail geriatric patients with cancer were at higher risk of chemotherapy-related adverse outcomes, such as grades 3-4 thrombocytopenia (odds ratio [OR] = 11.13, p = 0.021)”
Humansgeriatric cancer patients receiving chemotherapywithin 3 months of treatmentn = 234
Navitoclax raises the risk of thrombocytopenia in humans (29 patients).
“Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”
Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.
In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.
Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without…Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without carriers.